Dr. Peter Rose, MD
Claim this profileCleveland Clinic Foundation
Expert in Ovarian Cancer
Expert in Ovarian Tumors
25 reported clinical trials
50 drugs studied
About Peter Rose, MD
Education:
- Obtained MD from Boston University School of Medicine, 1981.
- Completed Surgery Residency at Vanderbilt University Medical Center, 1981-1983.
- Finished Obstetrics & Gynecology Residency at Ohio State University Medical Center, 1983-1986.
- Undertook Fellowship in Gynecologic Oncology at Roswell Park Cancer Institute, 1986-1988.
Experience:
- Boasts over 41 years of medical experience, specializing in Gynecologic Neoplasms.
- Serves as Section Head and Fellowship Director of Gynecologic Oncology at Cleveland Clinic.
- Holds board certifications in Obstetrics & Gynecology and Gynecologic Oncology.
- Faculty position as Professor of Obstetrics & Gynecology at Case Western Reserve University School of Medicine.
Area of expertise
1Ovarian Cancer
Global LeaderStage IV
Stage III
Stage II
2Ovarian Tumors
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Peter Rose, MD is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Ipatasertib + Megestrol Acetate
for Endometrial Cancer
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
Recruiting1 award Phase 1 & 2
More about Peter Rose, MD
Clinical Trial Related2 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Peter Rose, MD has experience with
- Carboplatin
- Bevacizumab
- Pembrolizumab
- Paclitaxel
- Olaparib
- Defactinib
Breakdown of trials Peter Rose, MD has run
Ovarian Cancer
Ovarian Tumors
Adenocarcinoma
Endometrioid Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Rose, MD specialize in?
Peter Rose, MD focuses on Ovarian Cancer and Ovarian Tumors. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Peter Rose, MD currently recruiting for clinical trials?
Yes, Peter Rose, MD is currently recruiting for 8 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Peter Rose, MD has studied deeply?
Yes, Peter Rose, MD has studied treatments such as Carboplatin, Bevacizumab, Pembrolizumab.
What is the best way to schedule an appointment with Peter Rose, MD?
Apply for one of the trials that Peter Rose, MD is conducting.
What is the office address of Peter Rose, MD?
The office of Peter Rose, MD is located at: Cleveland Clinic Foundation, Cleveland, Ohio 44195 United States. This is the address for their practice at the Cleveland Clinic Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.